A groundbreaking technology named Sturgeon is transforming tumor diagnosis during surgery, achieving rapid results in under 90 minutes. By focusing on specific parts of the cellular genome, it allows surgeons to start treatment with critical insights, even before operating. While the accuracy is impressive, challenges like intra-tumor heterogeneity and the need for specialized expertise remain hurdles to overcome.
